Prettysun Ang Mellow

Dr. Prettysun Ang Mellow

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2026 in Kidney and Dialysis
Verified
Journal Article
Open access
PDF file
Prettysun Ang MellowPrettysun Ang Mellow
Prettysun Ang Mellow
BWBendix Samarta Witarto
Bendix Samarta Witarto
AWAndro Pramana Witarto
Andro Pramana Witarto
I Ketut Adi SuryanaI Ketut Adi Suryana
I Ketut Adi Suryana
ATArtaria Tjempakasari
Artaria Tjempakasari
DSDjoko Santoso
Djoko Santoso
Introduction: Chronic kidney disease represents a significant global health burden, with dialysis as the most prevalent modality for end-stage kidney disease (ESKD) treatment. One of the major causes of ESKD is diabetes mellitus. Diabetic patients undergoing dialysis have higher mortality risk so optimal timing for its initiation is critical in maximizing survival and quality of life. This study aimed to explore the mortality risk of early versus late dialysis initiation in ESKD patients with diabetes. Methods: Systematic searches were conducted according to the PRISMA 2020 guidelines on PubMed, Scopus, ProQuest, and several databases through Web of Science up to 20 May 2025 (PROSPERO CRD420251074686). Effect sizes were presented as hazard ratios (HRs) with 95% confidence intervals (CIs) and 95% prediction intervals (PIs), pooled using a restricted maximum likelihood random-effects model. Subgroup and meta-regression analyses were also performed to search for potential confounding variables. Results: Eight studies involving 303,116 patients were included. Two studies defined early and late dialysis initiation using an estimated glomerular filtration rate (eGFR) cut-off of 5.0 mL/min/1.73 m2, while the remaining studies used cut-offs ranging from 7.0 to 7.7 mL/min/1.73 m2. The pooled hazard ratio (HR) showed no significant difference in the mortality risk between early and late initiation of dialysis in ESKD patients with diabetes mellitus (HR 1.02, 95% CI 0.79–1.31, p = 0.90, I2 = 97.87%, 95% PI 0.45–2.32). Sensitivity analysis showed that the pooled HR was robust. Subgroup analysis demonstrated no significant difference in the pooled HR according to different study designs. Meta-regressions also showed that the year of population sampling, mean age, and follow-up duration of mortality risk did not have significant associations with the pooled HR. Conclusions: Early dialysis initiation does not appear to confer a survival benefit in ESKD patients with diabetes mellitus. However, given the limited and heterogeneous evidence, further high-quality studies are needed. We suggest that dialysis initiation in this specific population should be guided by clinical indications.

1 April 2023 in Jurnal Widya Medika
Verified
Journal Article
Open access
PDF file
Prettysun Ang MellowPrettysun Ang Mellow
Prettysun Ang Mellow
Graves' disease is one of the most common autoimmune diseases. The disease is named after the scientist Robert James Graves, who first described it in the 19th century as a syndrome with an enlarged and overactive thyroid gland (hyperthyroidism due to circulating autoantibodies), rapid heart rate, and eye abnormalities. graves’ disease is the most common cause of hyperthyroidism and affects more women than men. Graves’ disease can appear at any age, but it most commonly appears for the first time between the ages of 20 and 40. Factor is a predisposition that is more dominant than environmental factors. There are circulating autoantibodies produced by B lymphocytes induced by autoreactive T lymphocytes that recognize thyrotropin-stimulating hormone (TSH) receptors in thyroid tissue as self-antigens. These autoantibodies are also known as TSH receptor antibodies (TSH-R Ab), thyrotropin stimulating antibodies (TSI), or thyrotropin receptor antibodies (TRAb). TRAb acts like TSH to cause thyroid hyperplasia (diffuse goitre), increased synthesis, and excessive and uncontrolled secretion of thyroid hormones (T4: tetraiodothyronine T4 and T3: triiodothyronine T3). Investigations to confirm Graves’ disease show elevated thyroid hormones (T4 and T3) with very low TSH and increased TRAb. On thyroid ultrasound, the majority of patients have a hypervascular and hypoechoic diffusely enlarged thyroid gland. The treatment for graves’ disease is to reduce the synthesis of thyroid hormones using anti-thyroid drugs, or to reduce the amount of thyroid tissue with radioactive iodine (RAI) or total thyroidectomy. Methimazole is the first-choice antithyroid drug with good effectiveness and safety. Although the recurrence rate after stopping the drug is still quite high